Global regulatory fragmentation: the critical challenge for drug-device combination products

Introduction Drug-device combination products (DDCPs) are becoming increasingly important in modern healthcare, enabling more precise, convenient, and patient-centered treatment through products such as prefilled syringes (PFS), autoinjectors, inhalers, infusion systems, and digitally enabled delivery tools. However, regulatory systems have not evolved at the same pace. Across major markets, these products are defined, classified, and reviewed in different ways, creating fragmented requirements for development, clinical investigation, marketing authorization, and lifecycle management. Methods By employing a structured comparative regulatory approach across major jurisdictions and analyzing publicly available regulatory frameworks, published guidance, and industry case studies, the research is qualitative in nature, reflecting expert consensus among the multi-company author group rather than a quantitative statistical study. Results This paper examines how these regulatory differences create uncertainty, duplication, delays, and additional burden for both developers and authorities, with direct consequences for timely patient access. It highlights key areas of misalignment, including terminology, regulatory pathways, clinical trial expectations, post-approval change management, and the limited use of reliance mechanisms. By comparing major regulatory approaches and illustrating practical examples from different regions, the paper shows that the current landscape is not fit for increasingly complex and globally developed DDCPs. Discussion Based on the results of the research the authors conclude that greater international convergence, clearer terminology, stronger coordination between medicinal product and medical device regulators, and broader use of reliance principles are needed to create a more predictable and efficient framework that supports innovation while protecting patients.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-17
DOI
https://doi.org/10.3389/fmed.2026.1938749
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Global regulatory fragmentation: the critical challenge for drug-device combination products

Henri Akouka, Fabio Bisordi, Prashant Bhatia, Michael kuehler et al.
Frontiers in Medicine
Healthcare Regulation
article

Global regulatory fragmentation: the critical challenge for drug-device combination products

Henri Akouka, Fabio Bisordi, Prashant Bhatia, Michael kuehler, Anurag Patel, Andreas Emmendoerffer, Katharine Duncan, Rumi Young, Sarah Adam
article en

Abstract

Introduction Drug-device combination products (DDCPs) are becoming increasingly important in modern healthcare, enabling more precise, convenient, and patient-centered treatment through products such as prefilled syringes (PFS), autoinjectors, inhalers, infusion systems, and digitally enabled delivery tools. However, regulatory systems have not evolved at the same pace. Across major markets, these products are defined, classified, and reviewed in different ways, creating fragmented requirements for development, clinical investigation, marketing authorization, and lifecycle management. Methods By employing a structured comparative regulatory approach across major jurisdictions and analyzing publicly available regulatory frameworks, published guidance, and industry case studies, the research is qualitative in nature, reflecting expert consensus among the multi-company author group rather than a quantitative statistical study. Results This paper examines how these regulatory differences create uncertainty, duplication, delays, and additional burden for both developers and authorities, with direct consequences for timely patient access. It highlights key areas of misalignment, including terminology, regulatory pathways, clinical trial expectations, post-approval change management, and the limited use of reliance mechanisms. By comparing major regulatory approaches and illustrating practical examples from different regions, the paper shows that the current landscape is not fit for increasingly complex and globally developed DDCPs. Discussion Based on the results of the research the authors conclude that greater international convergence, clearer terminology, stronger coordination between medicinal product and medical device regulators, and broader use of reliance principles are needed to create a more predictable and efficient framework that supports innovation while protecting patients.

Frontiers in MedicineVol. 13
F. Hoffmann-La Roche AG (CH), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), GlaxoSmithKline (United States) (US), AstraZeneca (United States) (US), Novo Holdings (Denmark) (DK), Teva Pharmaceuticals (Czechia) (CZ), Roche Pharma (Schweiz) AG (Switzerland) (CH), Bayer (Germany) (DE)
Good health and well-being
Healthcare Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon